Market Size (2024)
$7.67B
Vertical: HealthcareBase Year: 2024
Market Size (2024)
$7.67B
Projected (2035)
$12.69B
CAGR (2019–2035)
3.8%
Key Players
10+
This report covers Intensive Care Unit Market with forecasts from 2019 to 2035. 10 key companies are profiled.
The Intensive Care Unit Market market is projected to grow at a CAGR of 3.8% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The changing structure of the global Health System that has moved away from viewing critical care services as exclusively hospital-based to viewing critical care as a primary measure of national resilience has greatly affected the way in which ICUs will continue to evolve. This change can be seen through the combination of many of the clinical, demographic, regulatory, and technological aspects that are now present in the way hospitals build capacity, introduce innovation, and allocate resources. For example, the percentage of hospital expenditures allocated to critical care, as well as the number of ICU beds available, has increased within OECD countries over the last ten years due to a higher level of complexity of patients and longer hospitalization periods with older population demographics.
Likewise, as a continuation of the previous example, there is an increasing number of patients that will survive and continue to live with chronic conditions associated with these types of diseases based upon global population growth patterns. Due to the increasing numbers of patients that die globally from septic shock/sepsis, there is also an increased demand for the products that provide respiratory and renal support for patients who have acute respiratory illnesses, cardiovascular instability, or severe bacterial infections.
With evolving Federal and State governance structures in terms of clinical practice and emerging technologies, governments are investing heavily into building a digital healthcare infrastructure that supports the delivery of critical care services electronically while also improving the speed at which clinical care is delivered, improving patient safety, and improving clinical efficiencies. These governments are also developing new regulations that create a competitive marketplace for the development of AI systems, tele-ICU, and advanced life-support devices in the U.S., EU, and Asia-Pacific.
The ICU market is currently experiencing a transformation from many different directions due to a growing influence of structural, clinical, and technological changes representing the changing nature of critical care in today’s world. A major shift in this sector is the worldwide expansion of high acuity care due to the increasing prevalence of chronic disease. For example, hospitals in many countries in the Organization for Economic Cooperation and Development (OECD) have seen increases year over year in ICU admissions per capita as chronic disease continues to rise. Data from national health systems have demonstrated a steady rise in the percentage of patients who require organ support interventions during their hospital stay, with mechanical ventilation use increasing in numerous geographic areas over the last five years due primarily to an upward trend in respiratory illness, complexity of postoperative care, and the natural aging of the population.
One major trend is the rapid momentum that has been built around digitalization and telemedicine. Global investment by public healthcare systems in tele-critical care is on the increase. Significant improvements have been recorded by multiple large health systems, including the U.S. Veterans Health Administration, in terms of nighttime staff coverage and response times due to the development and deployment of virtual ICU command centers. The European Union and the Middle East also are beginning to adopt similar trajectories for digital health; emerging cross-border digital health frameworks are providing the basis for the establishment of interoperability among multiple hospitals. Government funding directed to predictive analytics, clinical decision support software, and connected device ecosystems are further reinforcing the transition to digital health.
As more countries recognize the need for the ICU community to be prepared for public health emergencies, the trend toward ICU preparedness as a public health responsibility grows. The majority of ICU preparedness programs were created following the impact of the COVID-19 pandemic, and many countries have modified their emergency response programs in response to this experience. New procurement guidelines in many countries now include the elements of equipment redundancy, local manufacturing capacity, oxygen autonomy, and modular ICU capacity. New areas of opportunity are now being opened for vendors to develop portable monitoring solutions, transport ventilators, and deployable negative-pressure environments in order to help meet the needs of hospitals and ICUs worldwide.
The need for advanced infection control systems driven by increased monitoring of antimicrobial resistance continues to push hospitals toward implementing advanced sterilization systems, closed-loop medication management systems, and contactless monitoring systems. Shortages of critical care staff in many hospitals are further accelerating the pace of innovation within the ICU, as increasing use of automation-first technologies to fill void created by shortages of trained intensivists and critical care nurses has easily become the norm.
Growth Parameters Mapped - Drivers
Rapid Population Ageing and Growth of High-Risk Cohorts
There is a Global demographic aging trend that indicates that population aging has put more than considerable pressure on Intensive Care Unit (ICU) services and: The WHO estimates that by 2030, there will be about 1 in 6 people aged 60 and over, resulting in the number of 60+ year-olds worldwide increasing from approximately 1 billion in 2020 and to 1.4 billion by 2030; by 2050, the estimated worldwide population of 60+ year-olds will double to 2.1 billion, and the estimated worldwide population aged 80+ year-olds will triple to approximately 426 million. In other words, the populations of 60+ year-olds and 80+ year-olds will continue to grow at nearly three times the overall population growth pattern. The elderly are also considered to be the most vulnerable populations, or the groups with the greatest potential for developing multiple organ systems failure (MSOF), sepsis and/or pneumonia.
The United Nations Department of Economic and Social Affairs (UN DESA) predicts in its 2023 World Population Aging Report that there are approximately 703 million people aged 65+ worldwide. The 2023 UN DESA report projects that by 2050, it is estimated to be approximately 1.5 billion people aged 65+ worldwide. In many areas, including high-income and upper-middle-income countries, the number of older adults (those aged 65+) is anticipated to be greater than 25% of the overall population. This demographic trend will have significant impacts on the case mix, or types of cases, presented to hospitals, with increasingly higher occurrences of older, frail, multi-morbid patients, and those with high-acuity needs. This trend will continue to impact the demand for equipment such as ventilators, hemodynamic monitors, renal support systems, and structured Geriatric ICU pathways.
Older patients tend to present with combinations of multiple chronic diseases such as coronary artery disease, chronic obstructive pulmonary disease (COPD), diabetes, renal impairment, and neurodegenerative diseases. The WHO indicates that these diseases produce age-related functional impairment, and because of these diseases, as well as polypharmacy and multiple chronic disease conditions, increase significantly the patient's risk of developing serious complications from a severe infection or acute medical event. Older patients tend to be at increased risk of requiring invasive ventilation or use of infusions/hypervolemia, hemodynamic support (vasopressors), and frequent fluid adjustment and continuous monitoring services that are typically provided in ICU facilities.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2024
Historical Period
2019 – 2023
Forecast Period
2025 – 2035
Primary Interviews
150+
Historical data (2019–2024) and forecast period (2024–2035)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter's Five Forces model offers a framework to study the global Intensive Care Unit market. Strategic business managers trying to gain an edge over competing firms in the global Intensive Care Unit market can utilize this model to better comprehend the company's industry. The components of each force and the degree of impact of each element in the context of the global Intensive Care Unit market have been broken down and analyzed.
Porter’s five forces model: Global Intensive Care Unit Market
Bargaining Power of Suppliers
The bargaining power of suppliers in the global Intensive Care Unit (ICU) market is anticipated to be somewhat moderate, driven primarily by the dual nature of the supply chain ecosystem. Manufacturers of ICUs purchase components such as sensors, valves, chips, medical-grade plastics, pumps and sterile consumables from many international suppliers, and therefore can spread out their purchasing and avoid complete dependence on one vendor. The worldwide location of a wide range of component manufacturers, particularly in East Asia, Europe and North America, creates an environment of robust competition and enables manufacturers to secure favourable pricing and terms for their services.
On the other hand, suppliers also have increased power in segments of the market where precision is critical or where suppliers have to comply with strict regulations. For example, Class III Ventilator Sub-Assy, Microelectronic Pressure Sensors, Biocompatible Polymers, Hepach Filters, Cybersecurity Modules. Additionally, vulnerabilities in the supply chain revealed by the COVID-19 pandemic have raised the importance of some upstream suppliers, particularly those who manufacture semiconductors and specialized medical sensors, whose shortages caused significant delays in production of equipment around the world. However, large manufacturers of ICUs protect themselves from the power of their suppliers through long-term contracts, dual sourcing, and vertical integration. Even though specialized suppliers exert power due to the criticality of their products and their compliance requirements, the ability of many global vendors to manufacture components, the developing locations for large regional manufacturing centres and the purchasing power of half a dozen major OEMs have created a balance against the significant power of specialized suppliers.
Hence, the bargaining power of suppliers in the global Intensive Care Unit market is expected to be moderate
Bargaining Power of Buyers
The bargaining position of buyers within the marketplace is high due to the fact that Industrial Unmanned Aerial Vehicles (ICUs) are being supplied by buyers that are well-organized and sophisticated (i.e. hospitals, health systems, government agencies and Group Purchasing Organizations [GPOs]). As a result, buyers generally have the ability to negotiate favourable pricing terms based on their ability to procure products in larger quantities, conduct competitive tenders, and place high demands on product performance and interoperability requirements in addition to Cybersecurity and service commitments. Furthermore, due to their size and their ability to conduct formal assessments and evaluations of potential suppliers, government agencies are particularly well-positioned to exert a powerful negotiating position on suppliers by requiring suppliers to enter into long-term service contracts with uptime guarantees and compliance audits. The incidence of COVID-19 has led to a greater level of scrutiny by buyers regarding the procurement of goods and services as they now require supply chain transparency, available redundant components, and multiple year maintenance and training plans.
The competitive environment created by the presence of multiple global OEMs with strong portfolios of ICU products, allows hospitals to establish a high degree of leverage on OEMs by enabling hospitals to perform careful price comparisons and lifecycle cost/benefit analyses, and evaluate the ability for the OEM to provide a comprehensive, integrated suite of products that can work in conjunction with the products already in use in their facility. The trend toward value-based procurement and the use of digital solutions for providing ICU services will continue to further empower buyers as they will continue to have higher levels of leverage when negotiating pricing, service or interoperability with suppliers. Based on their purchasing power, their standardisation of tendering processes, their demands for increased digital integration and their requirement for optimizing total cost of ownership, buyers will have strong negotiating leverage with OEMs.
Hence, the bargaining power of buyers in the global Intensive Care Unit market is expected to be high.
Threat of New Entrants
Despite a number of entry barriers in the ICU market, resulting in a low to moderate threat of new competition, the compliance obligations facing new entrants in terms of R&D and clinical validation will require a significant amount of cash as well as time for testing and putting through the regulatory processes (FPA, PMDA, and CE marking, Prime) plus maintaining strict post-market surveillance systems. All of this greatly increases both the length of time and the costs associated with launching into the ICU market. One of the primary advantages of the Large OEMs manufacturing equipment for ICU applications is the ability to take advantage of economies of scale in purchasing components and in providing service. It is difficult for small or emerging manufacturers to replicate and build up these advantages as they try to enter into the ICU market. Additionally, there is currently a significant shortage of nurses and other trained professionals available to provide high-quality, trained technical service and to offer adequate training and 24/7 support. Therefore, many ICU facilities are reliant on using OEM vendors to provide trained technicians and high-quality service to them.
Additionally, while software-focused startups and companies involved in AI-based applications can enter the ICU market via a tele-ICU analysis model or using an AI-based decision-support mechanism, their ability to compete directly with established hardware OEMs is limited since their products are completely dependent upon the established OEMs and may have a difficult time establishing a competitive position against the large OEMs. Despite the fact that new technologies (especially in AI, IoT and lighter-weight ventilator systems) will lead to new opportunities for specialized entrants into the ICU market, it is still very challenging to successfully enter.
Hence, the threat of new entrants in the global Intensive Care Unit market is expected to be low to moderate.
Threat of Substitutes
There are few substitutes to an ICU, and other settings cannot duplicate the high level of care that ICUs provide. Patients who need mechanical ventilation, intravenous fluids, renal support, continuous neurological monitoring, or invasive hemodynamic monitoring cannot receive adequate treatment in general medical floors or transitional care units. While advanced home ICUs and telemonitoring options may supplement the care of certain chronic patients, they cannot be substituted for acute cases of multiple organ failure. In addition, the increasing incidence of serious respiratory illnesses that cause a high rate of heart instability and sepsis is leading to an increase in the number of patients being hospitalised. The increased demand for ICU-specific environment due to the increase in global population age and non-communicable disease are creating further limitations on ICU substitutes. Since advanced care in critical care requires an environment that has state-of-the-art equipment, trained personnel, and tightly controlled environments, it is likely that there will be very few substitutes to critical care intervention.
Market estimates by geography (2035)
InsightSouth America leads with $596.42M by 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2024 | 2035 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $0.46M | $0.45M | $0.43M | -0.5% | 0% |
| Europe | $0.30M | $0.27M | $0.24M | -1.3% | 0% |
| Asia Pacific | $0.17M | $0.22M | $0.26M | 2.4% | 0% |
| Latin America | $0.04M | $0.04M | $0.05M | 1.3% | 0% |
| Middle East and Africa | $0.02M | $0.03M | $0.03M | 0.1% | 0% |
| South America | $267.02M | $375.40M | $596.42M | 5.2% | 100% |
| Total | $268.02M | $376.40M | $597.42M | 3.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$12.69B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Ventilators | $3.92B | 3.8% | 31% |
| Patients Monitors | $2.89B | 3.2% | 23% |
| Infusion Systems | $1.91B | 4.4% | 15% |
| Beds | $1.79B | 2.3% | 14% |
| Sphygmomanometer | $801.41M | 9.0% | 6% |
| Pulse oximeter | $746.87M | 6.0% | 6% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Intensive Care Unit Market covering market dynamics, competitive landscape, and strategic outlook.
The Intensive Care Unit Market market is projected to reach $12.69B by 2035, growing at 3.8% CAGR. The Ventilators segment holds the largest share.
Introduction
The changing structure of the global Health System that has moved away from viewing critical care services as exclusively hospital-based to viewing critical care as a primary measure of national resilience has greatly affected the way in which ICUs will continue to evolve. This change can be seen through the combination of many of the clinical, demographic, regulatory, and technological aspects that are now present in the way hospitals build capacity, introduce innovation, and allocate resources. For example, the percentage of hospital expenditures allocated to critical care, as well as the number of ICU beds available, has increased within OECD countries over the last ten years due to a higher level of complexity of patients and longer hospitalization periods with older population demographics.
Likewise, as a continuation of the previous example, there is an increasing number of patients that will survive and continue to live with chronic conditions associated with these types of diseases based upon global population growth patterns. Due to the increasing numbers of patients that die globally from septic shock/sepsis, there is also an increased demand for the products that provide respiratory and renal support for patients who have acute respiratory illnesses, cardiovascular instability, or severe bacterial infections.
With evolving Federal and State governance structures in terms of clinical practice and emerging technologies, governments are investing heavily into building a digital healthcare infrastructure that supports the delivery of critical care services electronically while also improving the speed at which clinical care is delivered, improving patient safety, and improving clinical efficiencies. These governments are also developing new regulations that create a competitive marketplace for the development of AI systems, tele-ICU, and advanced life-support devices in the U.S., EU, and Asia-Pacific.
The ICU market is currently experiencing a transformation from many different directions due to a growing influence of structural, clinical, and technological changes representing the changing nature of critical care in today’s world. A major shift in this sector is the worldwide expansion of high acuity care due to the increasing prevalence of chronic disease. For example, hospitals in many countries in the Organization for Economic Cooperation and Development (OECD) have seen increases year over year in ICU admissions per capita as chronic disease continues to rise. Data from national health systems have demonstrated a steady rise in the percentage of patients who require organ support interventions during their hospital stay, with mechanical ventilation use increasing in numerous geographic areas over the last five years due primarily to an upward trend in respiratory illness, complexity of postoperative care, and the natural aging of the population.
One major trend is the rapid momentum that has been built around digitalization and telemedicine. Global investment by public healthcare systems in tele-critical care is on the increase. Significant improvements have been recorded by multiple large health systems, including the U.S. Veterans Health Administration, in terms of nighttime staff coverage and response times due to the development and deployment of virtual ICU command centers. The European Union and the Middle East also are beginning to adopt similar trajectories for digital health; emerging cross-border digital health frameworks are providing the basis for the establishment of interoperability among multiple hospitals. Government funding directed to predictive analytics, clinical decision support software, and connected device ecosystems are further reinforcing the transition to digital health.
As more countries recognize the need for the ICU community to be prepared for public health emergencies, the trend toward ICU preparedness as a public health responsibility grows. The majority of ICU preparedness programs were created following the impact of the COVID-19 pandemic, and many countries have modified their emergency response programs in response to this experience. New procurement guidelines in many countries now include the elements of equipment redundancy, local manufacturing capacity, oxygen autonomy, and modular ICU capacity. New areas of opportunity are now being opened for vendors to develop portable monitoring solutions, transport ventilators, and deployable negative-pressure environments in order to help meet the needs of hospitals and ICUs worldwide.
The need for advanced infection control systems driven by increased monitoring of antimicrobial resistance continues to push hospitals toward implementing advanced sterilization systems, closed-loop medication management systems, and contactless monitoring systems. Shortages of critical care staff in many hospitals are further accelerating the pace of innovation within the ICU, as increasing use of automation-first technologies to fill void created by shortages of trained intensivists and critical care nurses has easily become the norm.
Growth Parameters Mapped - Drivers
Rapid Population Ageing and Growth of High-Risk Cohorts
There is a Global demographic aging trend that indicates that population aging has put more than considerable pressure on Intensive Care Unit (ICU) services and: The WHO estimates that by 2030, there will be about 1 in 6 people aged 60 and over, resulting in the number of 60+ year-olds worldwide increasing from approximately 1 billion in 2020 and to 1.4 billion by 2030; by 2050, the estimated worldwide population of 60+ year-olds will double to 2.1 billion, and the estimated worldwide population aged 80+ year-olds will triple to approximately 426 million. In other words, the populations of 60+ year-olds and 80+ year-olds will continue to grow at nearly three times the overall population growth pattern. The elderly are also considered to be the most vulnerable populations, or the groups with the greatest potential for developing multiple organ systems failure (MSOF), sepsis and/or pneumonia.
The United Nations Department of Economic and Social Affairs (UN DESA) predicts in its 2023 World Population Aging Report that there are approximately 703 million people aged 65+ worldwide. The 2023 UN DESA report projects that by 2050, it is estimated to be approximately 1.5 billion people aged 65+ worldwide. In many areas, including high-income and upper-middle-income countries, the number of older adults (those aged 65+) is anticipated to be greater than 25% of the overall population. This demographic trend will have significant impacts on the case mix, or types of cases, presented to hospitals, with increasingly higher occurrences of older, frail, multi-morbid patients, and those with high-acuity needs. This trend will continue to impact the demand for equipment such as ventilators, hemodynamic monitors, renal support systems, and structured Geriatric ICU pathways.
Older patients tend to present with combinations of multiple chronic diseases such as coronary artery disease, chronic obstructive pulmonary disease (COPD), diabetes, renal impairment, and neurodegenerative diseases. The WHO indicates that these diseases produce age-related functional impairment, and because of these diseases, as well as polypharmacy and multiple chronic disease conditions, increase significantly the patient's risk of developing serious complications from a severe infection or acute medical event. Older patients tend to be at increased risk of requiring invasive ventilation or use of infusions/hypervolemia, hemodynamic support (vasopressors), and frequent fluid adjustment and continuous monitoring services that are typically provided in ICU facilities.
-RISK COHORTS There is a Global demographic aging trend that indicates that population aging has put more than considerable pressure on Intensive Care Unit (ICU) services and: The WHO estimates that by 2030, there will be about 1 in 6 people aged 60 and over, resulting in the number of 60+ year-olds worldwide increasing from approximately 1 billion in 2020 and to 1.4 billion by 2030; by 2050, the estimated worldwide population of 60+ year-olds will double to 2.1 billion, and the estimated worldwide population aged 80+ year- olds will triple to approximately 426 million. In other words, the populations of 60+ year-olds and 80+ year-olds will continue to grow at nearly three times the overall population growth pattern. The elderly are also considered to be the most vulnerable populations, or the groups with the greatest potential for developing multiple organ systems failure (MSOF), sepsis and/or pneumonia. The United Nations Department of Economic and Social Affairs (UN DESA) predicts in its 2023 World Population Aging Report that there are approximately 703 million people aged 65+ worldwide. The 2023 UN DESA report projects that by 2050, it is estimated to be approximately 1.5 billion people aged 65+ worldwide.
In many areas, including high-income and upper-middle-income countries, the number of older adults (those aged 65+) is anticipated to be greater than 25% of the overall population. This demographic trend will have significant impacts on the case mix, or types of cases, presented to hospitals, with increasingly higher occurrences of older, frail, multi-morbid patients, and those with high-acuity needs. This trend will continue to impact the demand for equipment such as ventilators, hemodynamic monitors, renal support systems, and structured Geriatric ICU pathways. Older patients tend to present with combinations of multiple chronic diseases such as coronary artery disease, chronic obstructive pulmonary disease (COPD), diabetes, renal impairment, and neurodegenerative diseases. The WHO indicates that these diseases produce age-related functional impairment, and because of these diseases, as well as polypharmacy and multiple chronic disease conditions, increase significantly the patient's risk of developing serious complications from a severe infection or acute medical event. Older patients tend to be at increased risk of requiring invasive ventilation or use of infusions/hypervolemia, hemodynamic support (vasopressors), and frequent fluid adjustment and continuous monitoring services that are typically provided in ICU facilities. The rapid trend of population aging in these areas of Europe and East Asia is critical.
These areas have currently experienced or will likely experience this rapid population aging trend. Some countries in these areas will transition from aging to aged societies within 1 to 2 generations, creating an overflow of critically ill patients who will require ICU care services. Therefore, vendors or hospital systems must prepare to meet a higher demand for ICU capacity, especially for patients with complex cases and prolonged ICU hospitalization, as well as the anticipated higher demand for Geriatric ICU protocols, delirium prevention, and rehabilitation services, and ICU step down units. The increasing trends of population aging create the following market dynamic impacts: • An increase in the demand for base ICU Bed and ICU Equipment, regardless of whether there is a global pandemic or not; • Increased complexity of ICU care services, requiring increased use of integrated monitoring and decision support systems; and • Extended lengths of stay in ICU facilities creating higher demands for the more reliability of hospital devices and robust service maintenance agreements. In summary, population aging creates a continuing demand for the necessary infrastructure or equipment, and technology/service providers, to provide ICU services for patients over the next 20 to 30 years.
Currently, the primary medical reason for patients to be admitted to an Intensive Care Unit (ICU) is due to chronic illness (NCD) that is treated in the ICU. According to WHO (World Health Organization), chronic illnesses (NCDs) account for 74% of global mortality with the majority coming from 4 major chronic illnesses (cardiovascular disease, cancers, chronic respiratory disease, and diabetes). For example, in 2021, at least 19 million people died from cardiovascular disease, about 10 million from cancer, approximately 4 million from chronic respiratory disease, and over 2 million from diabetes (including those who developed kidney disease from diabetes). All of these chronic illnesses can result in acute symptoms, necessitating specialized care in an ICU, e.g. Myocardial Infarction with Cardiogenic Shock, Acute Stroke with Airway Compromise, Diabetic Ketoacidosis, and Acute-On-Chronic Respiratory Failure. However, it is important to note that while these deaths are endpoints, they represent a larger segment of the population that may suffer from recurrent acute illnesses. According to WHO, over 75% of ALL NCD deaths, and 86% of the 17 million NCDs in people who died prematurely (<70 years), occurred in LMICs.
Because of this unique situation, LMICs are experiencing an increasing burden of chronic illnesses while having very limited numbers of ICU beds and having to increase their investment in new ICU beds and develop areas for high dependency and basic organ support. Furthermore, NCDs interact with both Infection and Surgery. An individual with an underlying chronic illness, such as uncontrolled diabetes or heart failure, will be at a higher likelihood of requiring Ventilatory Support and Hemodynamic Monitoring than an
-ICU, INTEROPERABLE MONITORING, AND AI -ENABLED DECISION SUPPORT Digital-first approaches to critical care are emerging as one of the most significant opportunities for growth. Data from the U.S. illustrates how quickly tele-critical care services have grown. Between 2003 and 2010, adoption of tele-critical care services increased from 16 (0.4% of hospitals) to 213 (4.6%); the number of tele-critical care beds by the same hospitals increased dramatically during the same period. According to a more recent study, about 11% of non-federal hospitals in the U.S. currently support ICU patients using tele-critical care services. Data concerning patient outcomes is equally important. A systematic review of the use of telemedicine in critically ill patients suggests that tele-critical care services in a variety of settings have improved patient outcomes (lower mortality and lengths of stay) than standard ICU care. These factors combined create strong economic incentives for payers and providers to invest in telecritical care, especially for those facing staff shortages or geographically dispersed ICU beds. In addition to tele-critical care services, regulators encourage the use of other digital health tools and technologies as well. The U.S.
Food and Drug Administration (FDA) is developing a framework for the regulation of SaMD technologies and related products, the European Union (EU) has established AI regulation, and digital health initiatives in countries such as Japan and Singapore are offering new pathways to market for tele-critical care software. The potential for vendors and health systems includes: • Tele-critical care command centres that can monitor multiple hospitals, especially in areas that have inadequate intensive-care physician coverage • AI-enabled predictive tools for early warning signs (e.g., sepsis, unstable blood pressure), estimates of when to wean patients from the ventilator, and intelligent alarm management • Comprehensive platforms that integrate vital signs, laboratory test results, and imaging into one interface, enabling improved triage and the making of decisions regarding bed assignment and escalation C, AI “ ce-to- ” ICU; ICU.
C, marketplaces within North America, Europe, the Gulf, and parts of Asia are already standardizing on this suite of products and developing robust opportunities for future revenue (software license, predictive analytic products, remote monitoring). -FOCUSED ICU SOLUTIONS The emergence of Antimicrobial Resistance (AMR), as well as the increase in Hospital-Acquired Infections (HAIs), has greatly impacted the priorities of hospital investment in the Intensive Care Unit (ICU). According to the most comprehensive worldwide study done in 2019 by The Lancet, AMR caused 1.27 million deaths directly and indirectly affected nearly 4.95 million deaths via resistant infections making AMR a leading cause of mortality worldwide, on par with HIV and Malaria. The World Health Organization (WHO) has also projected AMR will create US$1 trillion in excess health care costs by 2050 and loss of Gross Domestic Product (GDP) between US$1 trillion and US$3.4 trillion annually by the year 2030 if not addressed urgently. The ICU is at the forefront of this epidemic; ventilator-associated pneumonia, catheter-related bloodstream infections, and multidrug-resistant organisms are more readily encountered in high-acuity units than any other area.
The addition of AMR to the National Action Plans and Global Health Security Agenda has placed greater pressure on hospitals to invest in their infrastructure and technology in infection prevention. This pressure to invest in infrastructure and technology has created numerous opportunities for hospitals in the form of: • Negative-pressure room isolation and modular isolation pods, as well as mobile biocontainment units to limit the potential for airborne transmission, • Advanced sterilization and disinfection systems (e.g., automated endoscope preprocessors, central sterile services upgrades, UV-C room disinfection, and hydrogen peroxide vapour), • Closed systems (infusion and catheter) that will reduce the risk of line-associated infections, • Monitoring systems to support antibiotic stewardship, real-time detection and reporting of outbreaks, and AMR surveillance. The available National and Regional Guidelines associated with infection control (e.g., CDC/ECDC/National Infection Control Agencies) are becoming stricter regarding the performance indicators for HAIs and have mandated hospitals to report these metrics. The penalties for failure to report accurately and timely (e.g., reimbursement, accreditation status, and public reports) have compelled hospitals to pursue tangible capital investments in Infection Control Engineering solutions, particularly in high acuity units like ICUs, where the consequences of failure are the most visible and financially significant.
The greatest business opportunity for manufacturers and solution providers is focused on integrated solutions, specifically, combinations of Environmental Controls, Device-Level Design (e.g., antimicrobial surface coatings), and Workflow Tools (e.g., checklists/analytics) into a cohesive ICU Infection Prevention Package that can go into CapEx and Operative Budgets and map to demonstrable reductions in the HAI and AMR indicators. -CARE MODELS FOR LMICS BACKED BY GLOBAL FINANCING Low- and middle-income nations (LMICs) experience ever-increasing NCD, trauma and surgical increases while beginning from minimal amounts of existing ICU infrastructure. A publicatio
Although ICU capacity is increasing, there are many limitations on the ability to expand this service, the primary limitation is the availability of human resources. Studies by university hospitals in the U.S. found that 81% of intensive care nurses have reported at least one symptom of BURNOUT and, therefore, intensive care units are some of the highest-stress occupations in healthcare. A more recent worldwide analysis of nurses in the ICU has identified BURNOUT as a significant risk of occupation for nurses. In addition, nurses comprise up to approximately 30% of a hospital's workforce and, therefore, the depletion of nurses is a systemic risk to Service continuity. Labour market data also demonstrates that there is a pipeline issue with the labour market for nursing in many high-income countries. For example, a report from the UK Nursing and Midwifery Council showed that the number of overseas nurses and midwives joining the UK registry fell by nearly 50% (from 12534 to 6321 new joiners) from April to September 2024; however, the number of overseas nurses that left increased.
Foreign-trained nurses account for many positions in ICUs and high-dependency units in high-income health systems, and therefore, the swings towards and away from the recruitment of nurses create limitations on the available capacity of ICU beds. Although the number of candidates is an important consideration, there are also many other considerations, particularly the mix of skills. Critical care positions require physicians (intensivists), respiratory therapists, perfusionists, and clinical pharmacists to .T W H O ’ 30, there will be a global shortage of tens of millions of doctors, nurses, and midwives due to lack of availability of workforce in low- and mid-income countries (LMICs). In addition, there will be significant shortages of healthcare workers for ICU services as ICU services require that nurses are present 24/7 and they require a high nurse-to-patient ratio. Therefore, the shortages will result in a direct impact on the number of ICU beds that are available and the also the number of patients that die unnecessarily.
In addition to a direct impact on the number of ICU beds that are available, this also results in a high mortality risk for patients that have experienced surge, and a slow rate of adaptation of advanced protocols that require highly trained staff. The COVID pandemic resulted in an increase in "burnout" and "moral injury" which aggravated the loss of skilled staff from the critical care service across many of the hospitals in the USA, evidenced by the fact that a significant number of experienced ICU staff have exited the profession or switched to practice areas with less intensity. As a result, a structural workforce limitation exists; therefore, unless a hospital has enough physical space for the placement of ICU beds and sufficient equipment to support each of the ICU beds, that hospital is unable to safely open or sustain all of its beds.
As a result of the structural workforce limitation, the ICU market is experiencing: • A slower increase of new ICU capacity in regions with a shortage of skilled workforce. • A larger need for automation, clinical decision support, and tele-ICU solutions to partially address the current situation of a shortage of ICU staff. • An increased emphasis on training and simulation, as well as the ergonomic design of devices to reduce cognitive and physical load on employees within intensive care units. In a strategic sense, human capital and not hardware will be the scarcest input in the ICU for the next ten years, and therefore, any vendor or policy that will provide meaningful assistance to this bottleneck is of high value. Care for the ICU represents one of the largest expenses for hospitals in the hospital industry and is therefore a limiting factor to the healthcare sector's growth as a whole. According to the Society of Critical Care Medicine, in the United States, total annual costs related to critical care had increased almost 92% from 2000 to 2010. This increase grew from $56.6 billion in 2000 to $108.9 billion by 2010.
Critical care made up about 13.2% of total hospital budgets, approximately 4.1% of total national health budgets, and roughly 0.72% of gross domestic product (GDP) in 2010. Patients in the ICU can expect to stay longer in the ICU than patients in the general wards. While in the ICU, patients consume a greater proportion of the hospital's resources, both human resources, staffing, and technical equipment/supplies as compared to patients located outside of the ICU. Therefore, the continued rise in operating expenses to hospitals, through all types of patients, is a compounded increase, as ICU patients cost many times more than patients who do not require ICU-level care. On a macroeconomic level, economies with larger healthcare resources tend to have greater capacity to cover the costs associated with maintaining a high-quality ICU. The OECD (Organization for Economic Co-operation and Development) has projected the average amount spent per person on health care among member states will be around $6,000 in 2024, with the United States having a higher average expenditure compared to other member countries.
This large difference between the U.S. and lower-income countries illustrates the limited ability of lower- to middle-income country governments to cover the high costs of the ICU, even when expenditures related to reducing the barriers to healthcare are expected to be higher. Furthermore, when governments are increasing their healthcare expenditures, they are usually spending those new revenues primarily on primary care, immunization, maternal and child health, and on
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Intensive Care Unit Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Deerfield, Illinois, US Founded: 1931 Workforce: ~50,000 Company Working: Baxter International Inc. (Baxter) is a Fortune 500 American health care company with headquarters in Deerfield, Illinois, US. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter is a leading producer of intravenous (IV) fluids and systems. It also manufactures infusion pumps, pre-filled syringes, biological sealants, and inhaled anesthetics, as well as dialyzers and other products for the treatment of end-stage renal disease. Its global footprint and critical nature of products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. As of December 31, 2018, Baxter manufactured products in over 20 countries and sold them in over 100 countries.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
17 interactive charts drawn from the Intensive Care Unit Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Intensive Care Unit Market By Segmental
Global Intensive Care Unit Market By Region
Global Intensive Care Unit Market By Lifesciences
Global Intensive Care Unit Market By Apac (Excluding China Region)
Global Intensive Care Unit Market By Pharmaceuticals
Global Intensive Care Unit Market By EMEA
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)